Genetic studies of heart transplantation outcomes
In the UMC Utrecht, we perform ~10-15 heart transplants each year. Although post-transplant patient care has improved tremendously over the past 50 years, patients still suffer from rejection and other complications after transplantation. High doses of immunosuppressive drugs are needed to avoid rejection, but cause an increased incidence of cancer and infections because of the resulting impaired functioning of the immune system. We are part of the International Genetics & Translational Research in Transplantation Network (iGeneTRAiN). Together with more than 20 other cohorts across the world, we aim to use genetics, proteomics, clinical data and a range of other studies to identify biological pathways responsible for clinical outcomes after (heart) transplantation. This includes acute rejection, vasculopathies, and pharmacogenomics.
Jessica van Setten
No courses available, internship possibilities in the future.
PMID: 26479416 B.J. Keating, J. van Setten et al Design and Implementation of the International Genetics and Translational Research in Transplantation Network. Transplantation. 2015;99(11):2401-12
PMID: 26423053 Y.R. Li, J. van Setten, et al Concept and design of a genome-wide association genotyping array tailored for transplantation-specific studies. Genome Med. 2015;7(1):90.